why choose us

First received: November 23, 2022

Clinical Trial: Ruxolitinib as add-on Therapy in Steroid-refractory Graft-vs-host Disease

Study Status: Completed

Recruit Status: Completed

Condition: Steroid Refractory GVHD

Study Type: Interventional


Official Title: Ruxolitinib Add-on in Steroid-refractory Graft-vs-host Disease After Allogeneic Stem Cell Transplantation: a Single Institutional Experience

Brief Summary: Steroid-refractory graft-vs-host disease (SR-GVHD) is a major cause of mortality after allogeneic hematopoietic stem cell transplantation (HSCT). We sought to evaluate the effect and safety of ruxolitinib (RUX) add-on in the treatment of patients with SR-GVHD.

Read more